Oncogenic epigenetic factor EP300 is a potential therapeutic target for bladder carcinoma

Puntos clave

• EP300 may act as a crucial oncogenic factor in bladder carcinoma, influencing tumor progression and resilience.
• Preliminary findings demonstrate that targeting EP300 could significantly inhibit bladder tumor growth in laboratory settings.
• Analysis involved investigating EP300's role in bladder carcinoma through genetic and biochemical techniques.
• Potential therapeutic strategies targeting EP300 highlight a novel approach in managing bladder carcinoma and warrant further investigation.